## Stephen P Mcdonald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/527844/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer Incidence Before and After Kidney Transplantation. JAMA - Journal of the American Medical Association, 2006, 296, 2823.	7.4	953
2	Long-Term Survival of Children with End-Stage Renal Disease. New England Journal of Medicine, 2004, 350, 2654-2662.	27.0	789
3	Vascular Access and All-Cause Mortality. Journal of the American Society of Nephrology: JASN, 2004, 15, 477-486.	6.1	384
4	Relationship between Dialysis Modality and Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 155-163.	6.1	282
5	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. American Journal of Kidney Diseases, 2017, 70, 464-475.	1.9	218
6	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	6.1	198
7	Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clinical Science, 2011, 120, 263-283.	4.3	188
8	Microbiology and Outcomes of Peritonitis in Australian Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2011, 31, 651-662.	2.3	183
9	Obesity Is Associated with Worse Peritoneal Dialysis Outcomes in the Australia and New Zealand Patient Populations. Journal of the American Society of Nephrology: JASN, 2003, 14, 2894-2901.	6.1	182
10	Reduction in Cardiovascular Death After Kidney Transplantation. Transplantation, 2010, 89, 851-857.	1.0	181
11	The pattern of excess cancer in dialysis and transplantation. Nephrology Dialysis Transplantation, 2009, 24, 3225-3231.	0.7	174
12	Effects of Body Mass Index at Transplant on Outcomes of Kidney Transplantation. Transplantation, 2007, 84, 981-987.	1.0	170
13	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2011, 58, 782-793.	1.9	168
14	The costâ€effectiveness of increasing kidney transplantation and homeâ€based dialysis. Nephrology, 2009, 14, 123-132.	1.6	166
15	Higher Peritoneal Transport Status Is Associated with Higher Mortality and Technique Failure in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Journal of the American Society of Nephrology: JASN, 2006, 17, 271-278.	6.1	159
16	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney International, 2010, 77, 904-912.	5.2	154
17	Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ: British Medical Journal, 2010, 340, c570-c570.	2.3	149
18	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop. American Journal of Kidney Diseases, 2017, 69, 97-107.	1.9	148

#	Article	IF	CITATIONS
19	Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrology Dialysis Transplantation, 2002, 17, 2212-2219.	0.7	147
20	Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney International, 2009, 76, 622-628.	5.2	134
21	Obesity is a Risk Factor for Peritonitis in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Peritoneal Dialysis International, 2004, 24, 340-346.	2.3	125
22	Lymphoproliferative Disease after Renal Transplantation in Australia and New Zealand. Transplantation, 2005, 80, 193-197.	1.0	122
23	Pregnancy Outcomes According to Dialysis Commencing Before or After Conception in Women with ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 143-149.	4.5	120
24	Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood, 2009, 114, 630-637.	1.4	115
25	Associations of Dialysis Modality and Infectious Mortality in Incident Dialysis Patients in Australia and New Zealand. American Journal of Kidney Diseases, 2009, 53, 290-297.	1.9	112
26	Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases, 2011, 58, 64-72.	1.9	110
27	Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. Kidney International, 2009, 76, 659-664.	5.2	103
28	Pseudomonas Peritonitis in Australia. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 957-964.	4.5	92
29	Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephrology, 2003, 8, 42-48.	1.6	85
30	Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1620-1628.	4.5	85
31	Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes in 435 Cases. American Journal of Kidney Diseases, 2010, 55, 690-697.	1.9	85
32	The impact of daily temperature on renal disease incidence: an ecological study. Environmental Health, 2017, 16, 114.	4.0	85
33	Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. American Journal of Kidney Diseases, 2004, 43, 492-501.	1.9	84
34	Staphylococcus Aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment, and Outcomes in 503 Cases. Peritoneal Dialysis International, 2010, 30, 311-319.	2.3	84
35	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2010, 25, 1973-1979.	0.7	84
36	Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clinical Transplantation, 2012, 26, E428-37.	1.6	84

#	Article	IF	CITATIONS
37	Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 1697-1707.	6.1	84
38	Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. Journal of the American Society of Nephrology: JASN, 2019, 30, 471-480.	6.1	81
39	Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. American Journal of Kidney Diseases, 2010, 55, 121-131.	1.9	80
40	Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrology Dialysis Transplantation, 2003, 18, 1555-1561.	0.7	77
41	Barriers to Timely Arteriovenous Fistula Creation: A Study of Providers and Patients. American Journal of Kidney Diseases, 2011, 57, 873-882.	1.9	76
42	Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology Dialysis Transplantation, 2012, 27, 3581-3587.	0.7	75
43	Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Peritoneal Dialysis International, 2004, 24, 340-6.	2.3	74
44	Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 561-569.	2.5	73
45	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	2.3	71
46	Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients. Circulation, 2019, 139, 2809-2818.	1.6	71
47	Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. Nephrology Dialysis Transplantation, 2010, 25, 1272-1278.	0.7	70
48	Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney International, 2003, 63, S123-S127.	5.2	69
49	Recurrence of IgA Nephropathy Among Renal Allograft Recipients From Living Donors is Greater Among Those With Zero HLA Mismatches. Transplantation, 2006, 82, 759-762.	1.0	68
50	Trends in Kidney Transplantation in Australia and New Zealand, 1993–2004. Transplantation, 2007, 84, 611-618.	1.0	68
51	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. Transplantation, 2017, 101, 1875-1886.	1.0	68
52	Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials, 2015, 16, 364.	1.6	67
53	Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2297-2303.	2.5	66
54	Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study. PLoS ONE, 2011, 6, e29563.	2.5	66

#	Article	IF	CITATIONS
55	Compared with Younger Peritoneal Dialysis Patients, Elderly Patients have Similar Peritonitis-Free Survival and Lower Risk of Technique Failure, but Higher Risk of Peritonitis-Related Mortality. Peritoneal Dialysis International, 2011, 31, 663-671.	2.3	66
56	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	1.9	66
57	Australia and New Zealand Dialysis and Transplant Registry. Kidney International Supplements, 2015, 5, 39-44.	14.2	65
58	The Impact of Total Ischemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation. Transplantation, 2017, 101, 1152-1158.	1.0	65
59	Increases in renal replacement therapy in Australia and New Zealand: Understanding trends in diabetic nephropathy. Nephrology, 2012, 17, 76-84.	1.6	64
60	ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA registry. American Journal of Kidney Diseases, 2002, 40, 1122-1131.	1.9	63
61	Relapsing and Recurrent Peritoneal Dialysis–Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	1.9	63
62	Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney International, 2010, 78, 408-414.	5.2	62
63	Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure forÂHemodialysis Vascular Access. American Journal of Kidney Diseases, 2018, 71, 690-700.	1.9	62
64	The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrology Dialysis Transplantation, 2004, 19, 678-685.	0.7	60
65	Albuminuria: Marker or target in indigenous populations. Kidney International, 2004, 66, S25-S31.	5.2	60
66	Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand. Pediatric Nephrology, 2009, 24, 1719-1726.	1.7	60
67	Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. Nephrology Dialysis Transplantation, 2010, 25, 3386-3392.	0.7	60
68	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney International, 2013, 83, 503-510.	5.2	59
69	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes and Endocrinology,the, 2017, 5, 26-33.	11.4	57
70	Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. Nephrology, 2005, 10, 192-197.	1.6	56
71	Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. Nephrology Dialysis Transplantation, 2011, 26, 3366-3372.	0.7	56
72	Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. Nephrology Dialysis Transplantation, 2011, 26, 702-708.	0.7	54

#	Article	IF	CITATIONS
73	Estimating the Total Incidence of Kidney Failure in Australia Including Individuals Who Are Not Treated by Dialysis or Transplantation. American Journal of Kidney Diseases, 2013, 61, 413-419.	1.9	54
74	Outcomes of Kidney Transplantation From Older Living Donors. Transplantation, 2013, 95, 106-113.	1.0	54
75	Center-Specific Factors Associated with Peritonitis Risk—A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	2.3	54
76	Post-Kidney Transplant Weight Change as Marker of Poor Survival Outcomes. Transplantation, 2008, 85, 1443-1448.	1.0	52
77	Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. BMC Nephrology, 2009, 10, 19.	1.8	52
78	Transplantation rates for living- but not deceased-donor kidneys vary with socioeconomic status in Australia. Kidney International, 2013, 83, 138-145.	5.2	51
79	Mycophenolate Versus Azathioprine for Kidney Transplantation. Transplantation, 2012, 94, 152-158.	1.0	49
80	The Association between Peritoneal Dialysis Modality and Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1091-1097.	4.5	49
81	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 96-103.	1.9	48
82	C-reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clinical Science, 2004, 106, 121-128.	4.3	46
83	Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. Nephrology Dialysis Transplantation, 2009, 24, 3834-3839.	0.7	46
84	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	5.2	44
85	Socio-economic status and incidence of renal replacement therapy: a registry study of Australian patients. Nephrology Dialysis Transplantation, 2012, 27, 4173-4180.	0.7	43
86	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 773-780.	4.5	43
87	Intensive Hemodialysis and Mortality Risk in Australian andÂNewÂZealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	1.9	42
88	Waiting Time and Outcome of Kidney Transplantation in Adolescents. Transplantation, 2006, 82, 1046-1050.	1.0	41
89	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783.	0.7	41
90	Australian registries—ANZDATA and ANZOD. Transplantation Reviews, 2013, 27, 46-49.	2.9	41

#	Article	IF	CITATIONS
91	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	1.9	41
92	Trends in incidence of treated endâ€stage renal disease, overall and by primary renal disease, in persons aged 20–64 years in Europe, Canada and the Asiaâ€Pacific region, 1998–2002. Nephrology, 2007, 12, 52	0-527.	40
93	Donor-recipient age matching improves years of graft function in deceased-donor kidney transplantation. Nephrology Dialysis Transplantation, 2010, 25, 3082-3089.	0.7	40
94	Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. BMJ, The, 2012, 345, e4657-e4657.	6.0	40
95	Renal replacement therapy in rural and urban Australia. Nephrology Dialysis Transplantation, 2012, 27, 2069-2076.	0.7	40
96	Validation of selfâ€reported cigarette smoking in a remote Australian Aboriginal community. Australian and New Zealand Journal of Public Health, 2003, 27, 57-60.	1.8	39
97	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 2018, 72, 62-74.	1.9	39
98	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrology Dialysis Transplantation, 2012, 27, 381-387.	0.7	38
99	Disparity of access to kidney transplantation by Indigenous and nonâ€Indigenous Australians. Medical Journal of Australia, 2018, 209, 261-266.	1.7	38
100	Carotid intima-media thickness, cardiovascular risk factors and albuminuria in a remote Australian Aboriginal community. Atherosclerosis, 2004, 177, 423-431.	0.8	37
101	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrology Dialysis Transplantation, 2013, 28, 455-461.	0.7	37
102	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	2.5	37
103	Risk Factors for Dialysis Withdrawal. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 775-781.	4.5	36
104	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. Journal of the National Cancer Institute, 2007, 99, 1340-1342.	6.3	35
105	Peritoneal Small Solute Clearance is Nonlinearly Related to Patient Survival in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Peritoneal Dialysis International, 2009, 29, 637-646.	2.3	35
106	Prevalence of genetic renal disease in children. Pediatric Nephrology, 2013, 28, 251-256.	1.7	35
107	Socioeconomic Differences in the Uptake of Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 929-935.	4.5	35
108	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1940-1947.	0.7	34

#	Article	IF	CITATIONS
109	Outcomes of Transplantation Using Kidneys From Donors Meeting Expanded Criteria in Australia and New Zealand, 1991 to 2005. Transplantation, 2009, 87, 1201-1209.	1.0	33
110	End-stage kidney disease due to sclerodermaoutcomes in 127 consecutive ANZDATA registry cases. Nephrology Dialysis Transplantation, 2011, 26, 3165-3171.	0.7	33
111	Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. American Journal of Kidney Diseases, 2019, 73, 300-308.	1.9	33
112	Recovery of renal function in end-stage renal failurecomparison between peritoneal dialysis and haemodialysis. Nephrology Dialysis Transplantation, 2009, 24, 2825-2831.	0.7	31
113	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. Nephrology Dialysis Transplantation, 2012, 27, 2028-2036.	0.7	31
114	Preâ€emptive renal transplantation from living donors in Australia: Effect on allograft and patient survival. Nephrology, 2008, 13, 535-540.	1.6	30
115	Predictors of Renal Recovery in Australian and New Zealand end-Stage Renal Failure Patients Treated with Peritoneal Dialysis. Peritoneal Dialysis International, 2007, 27, 184-191.	2.3	29
116	Trends in Hemodialysis Vascular Access From the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) 2000 to 2005. American Journal of Kidney Diseases, 2007, 50, 612-621.	1.9	29
117	Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Human Immunology, 2011, 72, 386-391.	2.4	29
118	The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation. Transplantation Direct, 2016, 2, e120.	1.6	29
119	Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1484-1492.	4.5	29
120	Using the excess heat factor to indicate heatwave-related urinary disease: a case study in Adelaide, South Australia. International Journal of Biometeorology, 2019, 63, 435-447.	3.0	29
121	Indigenous transplant outcomes in Australia: What the ANZDATA Registry tells us. Nephrology, 2004, 9, S138-S143.	1.6	28
122	Risk-Factor Profile of Living Kidney Donors. Transplantation, 2016, 100, 1278-1283.	1.0	28
123	The Association Between Age of Onset of Type 2 Diabetes and the Long-term Risk of End-Stage Kidney Disease: A National Registry Study. Diabetes Care, 2020, 43, 1788-1795.	8.6	28
124	Epidemiology of vascular access in the Australian hemodialysis population. Kidney International, 2003, 64, 1893-1902.	5.2	27
125	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. BMC Nephrology, 2012, 13, 41.	1.8	27
126	Obesity in pediatric kidney transplant recipients and the risks of acute rejection, graft loss and death. Pediatric Nephrology, 2017, 32, 1443-1450.	1.7	27

#	Article	IF	CITATIONS
127	PHYSICAL AND BIOCHEMICAL PREDICTORS OF DEATH IN AN AUSTRALIAN ABORIGINAL COHORT. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 618-621.	1.9	26
128	Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology, 2004, 9, 238-246.	1.6	26
129	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1556-1563.	4.5	26
130	Epidemiology and outcomes of peritonitis in children on peritoneal dialysis in Australasia. Pediatric Nephrology, 2010, 25, 1739-1745.	1.7	25
131	Access to waitlisting for deceased donor kidney transplantation in Australia. Nephrology, 2019, 24, 758-766.	1.6	25
132	External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. Nephrology Dialysis Transplantation, 2019, 34, 2127-2131.	0.7	24
133	Vascular access practice patterns in the New Zealand hemodialysis population. American Journal of Kidney Diseases, 2004, 43, 696-704.	1.9	23
134	Ageâ€specific risk of renal graft loss from late acute rejection or non ompliance in the adolescent and young adult period. Nephrology, 2018, 23, 585-591.	1.6	23
135	The prevalence and evidence-based management of needle fear in adults with chronic disease: A scoping review. PLoS ONE, 2021, 16, e0253048.	2.5	23
136	The Enigma of Hypertensive ESRD: Observations on Incidence and Trends in 18 European, Canadian, and Asian-Pacific Populations, 1998 to 2002. American Journal of Kidney Diseases, 2006, 48, 183-191.	1.9	22
137	Home haemodialysis in Australia — is the wheel turning full circle?. Medical Journal of Australia, 2010, 192, 403-406.	1.7	22
138	Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney International, 2002, 61, 2259-2265.	5.2	21
139	Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians. Nephrology, 2004, 9, 247-252.	1.6	21
140	Home hemodialysis in Australia: Current perspective. Hemodialysis International, 2008, 12, S6-S10.	0.9	21
141	End-stage kidney disease among indigenous peoples of Australia and New Zealand. Kidney International Supplements, 2013, 3, 170-173.	14.2	21
142	Indigenous patient experiences of returning to country: a qualitative evaluation on the Country Health SA Dialysis bus. BMC Health Services Research, 2018, 18, 1010.	2.2	21
143	Peritoneal dialysis in rural Australia. BMC Nephrology, 2013, 14, 278.	1.8	20
144	Racial disparities in pediatric kidney transplantation in <scp>N</scp> ew <scp>Z</scp> ealand. Pediatric Transplantation, 2014, 18, 689-697.	1.0	20

#	Article	IF	CITATIONS
145	Racial disparities in paediatric kidney transplantation. Pediatric Nephrology, 2014, 29, 125-132.	1.7	20
146	Residential Location and Kidney Transplant Outcomes in Indigenous Compared With Nonindigenous Australians. Transplantation, 2016, 100, 2168-2176.	1.0	20
147	The p53Pro72Arg Polymorphism is Associated with Albuminuria among Aboriginal Australians. Journal of the American Society of Nephrology: JASN, 2002, 13, 677-683.	6.1	20
148	Parental Donors in Live-Donor Kidney Transplantation Associated With Increased Rejection Rates and Reduced Glomerular Filtration Rates. Transplantation, 2007, 84, 972-980.	1.0	19
149	International quotidian dialysis registry: Annual report 2009. Hemodialysis International, 2009, 13, 240-249.	0.9	19
150	No excess risk of follicular lymphoma in kidney transplant and HIVâ€related immunodeficiency. International Journal of Cancer, 2010, 127, 2732-2735.	5.1	19
151	Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology, 2010, 15, 368-376.	1.6	19
152	Repeated Peritoneal Dialysis–Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2012, 59, 84-91.	1.9	19
153	Factors influencing reported rates of treated end-stage renal disease. Advances in Chronic Kidney Disease, 2005, 12, 32-38.	1.4	18
154	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2017, 37, 619-626.	2.3	18
155	The Spectrum of Adverse Pregnancy Outcomes Based on Kidney Disease Diagnoses: A 20-Year Population Study. American Journal of Nephrology, 2019, 49, 400-409.	3.1	18
156	Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991–2005. Nephrology, 2008, 13, 171-176.	1.6	17
157	Postâ€ŧransplant lymphoproliferative disorder: No relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients. Pediatric Transplantation, 2013, 17, 731-736.	1.0	17
158	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. Peritoneal Dialysis International, 2013, 33, 75-85.	2.3	17
159	International quotidian dialysis registry: Annual report 2010. Hemodialysis International, 2011, 15, 15-22.	0.9	16
160	Weekend Compared with Weekday Presentations of Peritoneal Dialysis–Associated Peritonitis. Peritoneal Dialysis International, 2012, 32, 516-524.	2.3	16
161	Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Nephrology, 2012, 17, 458-465.	1.6	16
162	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 450-459.	2.3	16

#	Article	IF	CITATIONS
163	Open and Laparoscopic Donor Nephrectomy: Activity and Outcomes From all Australasian Transplant Centers. Transplantation, 2010, 89, 1482-1488.	1.0	16
164	Feasibility and acceptability of e-PROMs data capture and feedback among patients receiving haemodialysis in the Symptom monitoring WIth Feedback Trial (SWIFT) pilot: protocol for a qualitative study in Australia. BMJ Open, 2020, 10, e039014.	1.9	16
165	Dialysis modality, vascular access and mortality in endâ€stage kidney disease: A biâ€national registryâ€based cohort study. Nephrology, 2016, 21, 878-886.	1.6	15
166	Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014). Population Health Metrics, 2017, 15, 7.	2.7	15
167	Effect on graft and patient survival between shipped and locally transplanted well-matched cadaveric renal allografts in Australia over a 10-year period. Nephrology, 2006, 11, 73-77.	1.6	14
168	High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 3005-3012.	0.7	14
169	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 397-406.	2.3	14
170	Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops. Nephrology Dialysis Transplantation, 2020, 35, 1585-1594.	0.7	14
171	Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 years. Nephrology Dialysis Transplantation, 2022, 37, 1152-1161.	0.7	13
172	Clustering and Residual Confounding in the Application of Marginal Structural Models: Dialysis Modality, Vascular Access, and Mortality. American Journal of Epidemiology, 2015, 182, 535-543.	3.4	12
173	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2018, 38, 257-265.	2.3	12
174	Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation. American Journal of Transplantation, 2019, 19, 3367-3376.	4.7	12
175	International collaborative efforts to establish kidney health surveillance systems. Kidney International, 2020, 98, 812-816.	5.2	12
176	Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. Peritoneal Dialysis International, 2007, 27, 184-91.	2.3	12
177	Morbidity burden of endâ€stage kidney disease in Australia: Hospital separation rates among people receiving kidney replacement therapy. Nephrology, 2011, 16, 758-766.	1.6	11
178	Organ Transplantation in Australia. Transplantation, 2017, 101, e345-e346.	1.0	11
179	Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Diabetes Care, 2021, 44, 1515-1523.	8.6	11
180	The International Quotidian Dialysis Registry: Annual report 2008. Hemodialysis International, 2008, 12, 281-289.	0.9	10

#	Article	IF	CITATIONS
181	Impending challenges of the burden of endâ€stage kidney disease in Australia. Medical Journal of Australia, 2019, 211, 374.	1.7	10
182	Associations between diabetes and sex with peritoneal dialysis technique and patient survival: Results from the Australia and New Zealand Dialysis and Transplant Registry cohort study. Peritoneal Dialysis International, 2021, 41, 57-68.	2.3	10
183	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. American Journal of Kidney Diseases, 2021, 78, 826-836.e1.	1.9	10
184	The Case of Azathioprine Versus Mycophenolate. Do Different Drugs Really Cause Different Transplant Outcomes?. Transplantation, 2009, 87, 803-804.	1.0	9
185	Interleukin-2 Receptor Antibody Reduces Rejection Rates and Graft Loss in Live-Donor Kidney Transplant Recipients. Transplantation, 2009, 88, 1208-1213.	1.0	9
186	Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transplant International, 2010, 23, 1207-1215.	1.6	9
187	DCD ECD Kidneys—Can You Make a Silk Purse From a Sow's Ear?. American Journal of Transplantation, 2013, 13, 249-250.	4.7	9
188	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	2.3	9
189	The psychosocial experiences and supportive care preferences of organ transplant recipients and their carers who live in regional Australia. Australian Journal of Rural Health, 2021, 29, 92-105.	1.5	9
190	Direct and indirect costs incurred by Australian living kidney donors. Nephrology, 2018, 23, 1145-1151.	1.6	8
191	REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) – design and baseline results. Kidney360, 2020, 1, 746-754.	2.1	8
192	Mortality After Home Hemodialysis Treatment Failure and Return to In-Center Hemodialysis. American Journal of Kidney Diseases, 2022, 79, 15-23.e1.	1.9	8
193	End-stage kidney disease due to haemolytic uraemic syndrome – outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrology, 2012, 13, 164.	1.8	7
194	Lack of impact of donor age on patient survival for renal transplant recipients ≥60 years. Transplant International, 2012, 25, 401-408.	1.6	7
195	Dialysis outcomes of elderly <scp>I</scp> ndigenous and nonâ€ <scp>I</scp> ndigenous <scp>A</scp> ustralians. Nephrology, 2014, 19, 610-616.	1.6	7
196	Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation. Kidney International, 2016, 89, 659-665.	5.2	7
197	Bowel health in chronic kidney disease: Patient perceptions differ from clinical definitions. Journal of Renal Care, 2018, 44, 65-72.	1.2	7
198	Weight change trajectories in Aboriginal and Torres Strait islander Australians after kidney transplantation: a cohort analysis using the Australia and New Zealand Dialysis and Transplant registry (ANZDATA). BMC Nephrology, 2019, 20, 232.	1.8	7

#	Article	IF	CITATIONS
199	Survival and transplant outcomes among young children requiring kidney replacement therapy. Pediatric Nephrology, 2021, 36, 2443-2452.	1.7	7
200	Isolated sphenoid fungal sinusitis in a renal transplant recipient presenting with bilateral abducens nerve palsy. Transplant International, 2007, 20, 640-642.	1.6	6
201	Comparable transplant outcomes between local and shipped deceasedâ€donor kidneys in Australia: Analysis of Australia and New Zealand Dialysis and Transplant Registry 1992–2007. Nephrology, 2010, 15, 124-132.	1.6	6
202	A review of utilityâ€based allocation strategies to maximize graft years of deceased donor kidneys. Nephrology, 2011, 16, 368-376.	1.6	6
203	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2657-2661.	4.5	6
204	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	6.1	6
205	Projecting demands for renal replacement therapy in the Northern Territory: a stochastic Markov model. Australian Health Review, 2018, 42, 380.	1.1	6
206	Two pregnancies after simultaneous pancreas–kidney transplantation: A case report. Obstetric Medicine, 2020, 13, 92-95.	1.1	6
207	Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand. Nephrology, 2021, 26, 814-823.	1.6	6
208	Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial. BMJ, The, 2022, 377, e069634.	6.0	6
209	Australians with renal disease: a new national survey. Medical Journal of Australia, 1999, 171, 444-444.	1.7	5
210	Interfaces between cardiovascular and kidney disease among Aboriginal Australians. Advances in Chronic Kidney Disease, 2005, 12, 39-48.	1.4	5
211	Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research. Kidney International, 2020, 98, 572-578.	5.2	5
212	Pregnancy outcomes for simultaneous Pancreas–Kidney transplant recipients versus kidney transplant recipients. Clinical Transplantation, 2021, 35, e14151.	1.6	5
213	Shifting Power to Improve First Nation Peoples' Access and Outcomes in Kidney Care. Kidney Medicine, 2021, 3, 881-882.	2.0	5
214	Perspectives of Patients, Nurses, and Nephrologists About Electronic Symptom Monitoring With Feedback in Hemodialysis Care. American Journal of Kidney Diseases, 2022, 80, 215-226.e1.	1.9	5
215	Association between initial and pretransplant dialysis modality and graft and patient outcomes in live- and deceased-donor renal transplant recipients. Transplant International, 2012, 25, 1032-1040.	1.6	4
216	Does equal care give equal outcomes?. Kidney International, 2013, 84, 647-650.	5.2	4

#	Article	IF	CITATIONS
217	Placing Aboriginal kidney disease in context. Cmaj, 2014, 186, 93-94.	2.0	4
218	Daily hemodialysis practices in Australia/New Zealand and in France: a comparative cohort study. BMC Nephrology, 2019, 20, 156.	1.8	4
219	Fatherhood and Kidney Replacement Therapy: Analysis of the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry. American Journal of Kidney Diseases, 2020, 76, 444-446.	1.9	4
220	Healthcare professional and community preferences in deceased donor kidney allocation: A best-worst scaling survey. American Journal of Transplantation, 2022, 22, 886-897.	4.7	4
221	Kidney Disease Among Aboriginal and Torres Strait Islander People in Australia. , 2017, , 167-180.		3
222	Impact of supplemental private health insurance on dialysis and outcomes. Internal Medicine Journal, 2020, 50, 542-549.	0.8	3
223	Insights into the labeling effect of Kidney Donor Performance Index reporting: The Australian experience. American Journal of Transplantation, 2020, 20, 870-878.	4.7	3
224	ABO blood group relationships to kidney transplant recipient and graft outcomes. PLoS ONE, 2020, 15, e0236396.	2.5	3
225	Changes in excess mortality among adults with diabetes-related end-stage kidney disease: a comparison between the USA and Australia. Nephrology Dialysis Transplantation, 2022, 37, 2004-2013.	0.7	3
226	Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation. Transplant International, 2022, 36, 10199.	1.6	3
227	FO031THE SYMPTOM MONITORING WITH FEEDBACK TRIAL (SWIFT): A NOVEL REGISTRY-BASED CLUSTER RANDOMISED CONTROLLED TRIAL AMONG AUSTRALIAN AND NEW ZEALAND ADULTS WITH END-STAGE KIDNEY DISEASE MANAGED ON HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	2
228	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. Kidney360, 2021, 2, 674-683.	2.1	2
229	Gastrointestinal symptom burden and dietary intake in patients with chronic kidney disease. Journal of Renal Care, 2021, 47, 234-241.	1.2	2
230	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	1.6	2
231	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	2.3	2
232	Excess all ause and causeâ€specific mortality for people with diabetes and endâ€stage kidney disease. Diabetic Medicine, 2022, 39, e14775.	2.3	2
233	Erythropoietic agents, iron and hemoglobin-What happens beyond the trial setting: Observational data from the ANZDATA Registry. Hemodialysis International, 2004, 8, 257-264.	0.9	1
234	Progression of polycystic kidney disease—a lack of progress?. Nature Reviews Nephrology, 2014, 10, 489-491.	9.6	1

#	Article	IF	CITATIONS
235	The IDEAL trial in Australia and New Zealand: clinical and economic impact. Nephrology Dialysis Transplantation, 2021, 37, 168-174.	0.7	1
236	Obesity in dialysis patients – What is the problem?. Obesity Research and Clinical Practice, 2021, 15, 413-414.	1.8	1
237	Evaluating data quality in the Australian and New Zealand dialysis and transplant registry using administrative hospital admission datasets and data-linkage. Health Information Management Journal, 0, , 183335832210977.	1.2	1
238	Living Kidney Donor Outcomes—More Pieces to the Jigsaw. Transplantation, 2015, 99, 1547-1548.	1.0	0
239	Editorial: RRT in South Africa - and the relevance of Registries. Nephrology, 2017, 22, 581-582.	1.6	0
240	International travel by Australians for overseas transplantation. Medical Journal of Australia, 2019, 211, 460-460.	1.7	0
241	Response by Rao et al to Letter Regarding Article, "Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients― Circulation, 2019, 140, e806-e807. –	1.6	0
242	A retrospective caseâ€control study exploring preâ€transplant predictors for loss of kidney transplant function or death among Indigenous kidney transplant recipients. Internal Medicine Journal, 2021, , .	0.8	0